# CODING RESOURCE

FluMist®
Influenza Vaccine
Live, Intranasal

## National Drug Code (NDC)

The National Drug Code (NDC) is a universal, unique, 3-segment number identifying drugs by manufacturer, dosage, and package size. Payers may require the submission of the 11-digit NDC on health care claim forms, and electronic claims may be denied for drugs billed without a valid 11-digit NDC. Contact your patient's health plan to determine claim submission requirements and to determine accurate reporting of NDC codes.

### 10-digit NDC

| Dosage | Code | Package |
|---|---|---|
| FluMist Trivalent 0.2mL Single Intranasal Sprayer 2025/2026 | 66019-112-00 | Single Sprayer |
| FluMist Trivalent 0.2mL 2025/2026 (10 Intranasal Sprayers in Carton) | 66019-112-10 | Carton |

### 11-digit NDC

| Dosage | Code | Package |
|---|---|---|
| FluMist Trivalent 0.2mL Single Intranasal Sprayer 2025/2026 | 66019-0112-00 | Single Sprayer |
| FluMist Trivalent 0.2mL 2025/2026 (10 Intranasal Sprayers in Carton) | 66019-0112-10 | Carton |

## IMPORTANT SAFETY INFORMATION

- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction
- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST

# CODING RESOURCE

FluMist®
Influenza Vaccine
Live, Intranasal

## Current Procedural Terminology (CPT®)

Submitting accurate codes and claims is important to ensure proper reimbursement of services. The chart below lists the potential Current Procedural Terminology (CPT) code for your reference when submitting claims for your FLUMIST patients.

| Code | Description |
|---|---|
| **VACCINE PRODUCT CPT CODE** | |
| **90660** | Influenza virus vaccine, trivalent, live (LAIV3) for intranasal use |
| **PEDIATRIC IMMUNIZATION ADMINISTRATION CPT CODES FOR PATIENTS ≤18 YEARS OF AGE** | |
| **90460** | Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered |
| **90461** | Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure) |
| **ADULT IMMUNIZATION ADMINISTRATION CPT CODES FOR PATIENTS >18 YEARS OF AGE** | |
| **90473** | Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid) (Do not use 90473 in conjunction with 90471) |
| **90474** | Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90474 in conjunction with 90471 or 90473) |

## IMPORTANT SAFETY INFORMATION (CONT'D)

- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
- The effectiveness of FLUMIST has not been studied in immunocompromised persons

# CODING RESOURCE

FluMist
Influenza Vaccine
Live, Intranasal

## Diagnosis Codes

When filing claims, providers often indicate a diagnosis code reflecting the patient's condition. Based on the Indications for FLUMIST, an example of a diagnosis code that may be appropriate is listed below.

It is important to note that the code identified below is an example only. Each provider is responsible for ensuring all coding is accurate and documented in the medical record based on the condition of the patient.

The use of the following code does not guarantee reimbursement.

| ICD-10-CM | Description |
|---|---|
| **Z23** | Encounter for immunization |

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

## IMPORTANT SAFETY INFORMATION (CONT'D)

- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
- FLUMIST may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

## INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

**Please see additional Important Safety Information on adjacent pages and full Prescribing Information, including Patient Information and Instructions for Use.**

# CODING RESOURCE

FluMist
Influenza Vaccine
Live, Intranasal

## INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

## IMPORTANT SAFETY INFORMATION

- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction
- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
- The effectiveness of FLUMIST has not been studied in immunocompromised persons
- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
- FLUMIST may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

**Please see full Prescribing Information, including Patient Information and Instructions for Use.**

*You may report side effects related to AstraZeneca products.*


1-877-FLUMIST (358-6478) **www.FlumistHCP.com**

AstraZeneca